Using hybrid nanoparticles to treat triple-negative breast cancer
Multimodal hybrid nanoparticles for the treatment of triple-negative breast cancer
['FUNDING_R15'] · UNIVERSITY OF NORTH CAROLINA CHARLOTTE · NIH-10514997
This study is testing a new treatment for triple-negative breast cancer that uses special tiny particles to deliver medicine directly to cancer cells, aiming to work better and cause fewer side effects than traditional chemotherapy, which could help patients facing this tough diagnosis.
Quick facts
| Phase | ['FUNDING_R15'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF NORTH CAROLINA CHARLOTTE (nih funded) |
| Locations | 1 site (CHARLOTTE, UNITED STATES) |
| Trial ID | NIH-10514997 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative hybrid nanoparticles that combine therapeutic nucleic acids and photodynamic therapy to treat triple-negative breast cancer (TNBC). The approach aims to overcome the limitations of conventional chemotherapy by targeting the cancer cells more effectively while minimizing side effects. Patients with TNBC, who often face poor prognosis and high recurrence rates, may benefit from this novel treatment strategy. The research involves in vitro experiments to evaluate the efficacy of these nanoparticles in combating TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer, particularly those who have not responded well to standard treatments.
Not a fit: Patients with other subtypes of breast cancer or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and less harmful treatment option for patients with triple-negative breast cancer.
How similar studies have performed: While the use of nanoparticles in cancer treatment is an emerging field, this specific combination of therapeutic nucleic acids and photodynamic therapy for TNBC is relatively novel and has not been extensively tested.
Where this research is happening
CHARLOTTE, UNITED STATES
- UNIVERSITY OF NORTH CAROLINA CHARLOTTE — CHARLOTTE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: VIVERO-ESCOTO, JUAN LUIS — UNIVERSITY OF NORTH CAROLINA CHARLOTTE
- Study coordinator: VIVERO-ESCOTO, JUAN LUIS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: American Cancer Society, Breast Cancer